BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled to take place on September 14-16, 2026, in New York City.
During the conference, BioVersys' Chief Financial Officer, Hernan Levett, will deliver a live presentation on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace. Additionally, a pre-recorded on-demand presentation by CEO Dr. Marc Gitzinger will be available starting September 11, 2026, at 7:00 AM ET, with replays accessible for 90 days via the H.C. Wainwright platform or the BioVersys website.
The company's participation at this premier investment conference underscores its ongoing efforts to secure funding and partnerships to advance its pipeline. BioVersys is dedicated to addressing the growing global health threat of antimicrobial resistance (AMR), which the World Health Organization has identified as one of the top public health threats. The company's portfolio includes two internal technology platforms: TRIC and Ansamycin Chemistry. These platforms enable the design of candidates that overcome resistance mechanisms, block virulence production, and directly affect bacterial pathogenesis, aiming to provide new treatment options in the antimicrobial and microbiome fields.
BioVersys' most advanced programs target nosocomial infections caused by Acinetobacter baumannii (BV100, currently in Phase 3) and tuberculosis (alpibectir, in Phase 2, developed in collaboration with GlaxoSmithKline (GSK) and a consortium including the University of Lille, France). These programs address critical unmet medical needs, as MDR bacteria cause an estimated 700,000 deaths annually worldwide, a number that could rise to 10 million by 2050 if no action is taken.
The H.C. Wainwright conference provides a platform for BioVersys to engage with investors and industry peers, potentially facilitating collaborations and financial support. The company's CEO and CFO will be available for one-on-one meetings with registered attendees, as arranged through H.C. Wainwright representatives.
BioVersys is headquartered in Basel, Switzerland, a leading biotech hub. The company's commitment to innovation in antimicrobial research is timely, as the world grapples with the dual challenges of increasing antibiotic resistance and the slow pace of new antibiotic development. By presenting at the conference, BioVersys aims to highlight its progress and the importance of continued investment in this critical area of medicine.
